Novartis (VTX:NOVN) Full Year 2022 Results

Key Financial Results

• Revenue: US$51.8b (down 2.0% from FY 2021).

• Net income: US$6.96b (down 71% from FY 2021).

• Profit margin: 13% (down from 45% in FY 2021). The decrease in margin was primarily driven by higher expenses.

• EPS: US$3.19 (down from US$10.71 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Novartis Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Switzerland.

The company's shares are down 5.3% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Novartis that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here